
Case Report Explores Caplacizumab in Late-Diagnosed Congenital Thrombotic Thrombocytopenic Purpura
A newly published clinical case report details the rapid hematologic improvement and subsequent disease course of a 74-year-old patient with congenital thrombotic thrombocytopenic purpura who received the anti-von Willebrand factor nanobody caplacizumab in



